Vaccine Development for Prescottella Equi

Procedia in vaccinology Pub Date : 2014-01-01 DOI:10.1016/j.provac.2014.07.009

T. Vanniasinkam , C. Giles , S. Ndi , M. Heuzenroeder , M. Barton

{"title":"Vaccine Development for Prescottella Equi","authors":"T. Vanniasinkam , C. Giles , S. Ndi , M. Heuzenroeder , M. Barton","doi":"10.1016/j.provac.2014.07.009","DOIUrl":null,"url":null,"abstract":"<div>Prescottella equi (formerly Rhodococcus equi) is an intracellular pathogen that causes pyogranulomatous pneumonia in Thoroughbred foals. There is currently no vaccine available for the prevention of this disease in foals despite years of research. Cell mediated immunity is considered crucial for overcoming an infection caused by this pathogen. The virulence associated protein (VapA) is a well characterized immunogenic protein associated with this pathogen and was used to develop DNA and recombinant protein vaccines in this study. Vaccine candidates and live P. equi based vaccine were tested in BALB/c mice. Mice were challenged with virulent P.equi 2 weeks following the last boost and IgG subtypes and bacterial clearance from spleen and liver determined. The DNA vaccine elicited a significant IgG2a response indicating a Th1 biased immune response. The IFN gamma response from DNA and recombinant VapA vaccinated mice was moderate. The results of the challenge study showed that neither the recombinant VapA protein nor DNA vaccine enhanced clearance of P. equi in this model.</div>","PeriodicalId":89221,"journal":{"name":"Procedia in vaccinology","volume":"8 ","pages":"Pages 50-57"},"PeriodicalIF":0.0000,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.provac.2014.07.009","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Procedia in vaccinology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1877282X14000101","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Prescottella equi (formerly Rhodococcus equi) is an intracellular pathogen that causes pyogranulomatous pneumonia in Thoroughbred foals. There is currently no vaccine available for the prevention of this disease in foals despite years of research. Cell mediated immunity is considered crucial for overcoming an infection caused by this pathogen. The virulence associated protein (VapA) is a well characterized immunogenic protein associated with this pathogen and was used to develop DNA and recombinant protein vaccines in this study. Vaccine candidates and live P. equi based vaccine were tested in BALB/c mice. Mice were challenged with virulent P.equi 2 weeks following the last boost and IgG subtypes and bacterial clearance from spleen and liver determined. The DNA vaccine elicited a significant IgG2a response indicating a Th1 biased immune response. The IFN gamma response from DNA and recombinant VapA vaccinated mice was moderate. The results of the challenge study showed that neither the recombinant VapA protein nor DNA vaccine enhanced clearance of P. equi in this model.

查看原文本刊更多论文

马Prescottella的疫苗研制

马Prescottella(原马红球菌)是一种细胞内病原体，可引起纯种马驹脓肉芽肿性肺炎。尽管经过多年的研究，目前还没有预防马驹这种疾病的疫苗。细胞介导免疫被认为是克服由这种病原体引起的感染的关键。毒力相关蛋白(vir毒力相关蛋白，VapA)是一种特性良好的与该病原体相关的免疫原性蛋白，在本研究中被用于开发DNA和重组蛋白疫苗。在BALB/c小鼠身上试验了候选疫苗和马弓形虫活疫苗。在最后一次增强后2周，用毒力强的马棘球蚴攻击小鼠，测定脾脏和肝脏的IgG亚型和细菌清除率。DNA疫苗引起了显著的IgG2a应答，表明Th1偏向性免疫应答。DNA和重组VapA疫苗小鼠的IFN γ反应是中等的。攻毒研究结果表明，重组VapA蛋白和DNA疫苗均不能提高该模型对马链球菌的清除率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Procedia in vaccinology

自引率

0.00%

发文量